BHV-8000, a Selective Brain-penetrant TYK2/JAK1 Inhibitor in Development for Neuroinflammatory and Neurodegenerative Diseases, Demonstrates Efficacy in an Alpha-Synuclein Overexpressing Parkinson’s Disease Mouse Model (S4.006)
To assess the effects of an investigational TYK2/JAK1 inhibitor on behavioral and histopathologic outcomes in an α-Syn overexpressing Parkinson’s disease (PD) mouse model
Authors
- Bruce D. Car
- Wei Tang (ORCID: https://orcid.org/0000-0001-8879-8325)
- Irfan Qureshi (ORCID: https://orcid.org/0000-0002-0572-0993)
- Bavani Shankar
- Lindsey Lair (ORCID: https://orcid.org/0000-0002-5961-482X)
- Vlad Coric
- Chris Liang
Institutions
- Biohaven Pharmaceuticals (United States) (US)
- Pharmac (NZ)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208701
- Primary Topic
- Nuclear Receptors and Signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.00